1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Erdmann F, Lortet-Tieulent J, Schüz J,
Zeeb H, Greinert R, Breitbart EW and Bray F: International trends
in the incidence of malignant melanoma 1953-2008-are recent
generations at higher or lower risk? Int J Cancer. 132:385–400.
2013. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E586. 2015.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Lee ML, Tomsu K and Von Eschen KB:
Duration of survival for disseminated malignant melanoma: Results
of a meta-analysis. Melanoma Res. 10:81–92. 2000.PubMed/NCBI
|
5
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
6
|
Baderca F, Vincze D, Balica N and Solovan
C: Mucosal melanomas in the elderly: Challenging cases and review
of the literature. Clin Interv Aging. 9:929–937. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Nordlund JJ: The lives of pigment cells.
Clin Geriatr Med. 5:91–108. 1989.PubMed/NCBI
|
8
|
Chang AE, Karnell LH and Menck HR: The
National Cancer Data Base report on cutaneous and noncutaneous
melanoma: A summary of 84,836 cases from the past decade. The
American College of Surgeons Commission on Cancer and the American
Cancer Society. Cancer. 83:1664–1678. 1998. View Article : Google Scholar : PubMed/NCBI
|
9
|
Umeda M, Mishima Y, Teranobu O, Nakanishi
K and Shimada K: Heterogeneity of primary malignant melanomas in
oral mucosa: An analysis of 43 cases in Japan. Pathology.
20:234–241. 1988. View Article : Google Scholar : PubMed/NCBI
|
10
|
Fujisawa Y, Takahashi T, Yamamoto A,
Yamazaki N, Saida T and Ishihara K: Ohtsuka: Statistics for
malignant melanoma in Japan: A nationwide survey conductied during
the calender years 2006 2007. Skin Cancer. 23:267–279. 2008.
View Article : Google Scholar
|
11
|
Chen H, Cai Y, Liu Y, He J, Hu Y, Xiao Q,
Hu W and Ding K: Incidence, surgical treatment, and prognosis of
anorectal melanoma from 1973 to 2011: A population-based SEER
analysis. Medicine (Baltimore). 95:e27702016. View Article : Google Scholar : PubMed/NCBI
|
12
|
Arai T, Yanagisawa A, Kondo F, Aida J and
Takubo K: Clinicopathologic characteristics of esophageal primary
malignant melanoma. Esophagus. 13:17–24. 2016. View Article : Google Scholar
|
13
|
Cheung MC, Perez EA, Molina MA, Jin X,
Gutierrez JC, Franceschi D, Livingstone AS and Koniaris LG:
Defining the role of surgery for primary gastrointestinal tract
melanoma. J Gastrointest Surg. 12:731–738. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Fang D, Nguyen TK, Leishear K, Finko R,
Kulp AN, Hotz S, van Belle PA, Xu X, Elder DE and Herlyn M: A
tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 65:9328–9337. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
16
|
Schatton T, Murphy GF, Frank NY, Yamaura
K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM,
Weishaupt C, et al: Identification of cells initiating human
melanomas. Nature. 451:345–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
17
|
Brinckerhoff CE: Cancer stem cells (CSCs)
in melanoma: There's smoke, but is there fire? J Cell Physiol.
232:2674–2678. 2017. View Article : Google Scholar : PubMed/NCBI
|
18
|
Klein WM, Wu BP, Zhao S, Wu H,
Klein-Szanto AJ and Tahan SR: Increased expression of stem cell
markers in malignant melanoma. Mod Pathol. 20:102–107. 2007.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Tanaka S, Kamachi Y, Tanouchi A, Hamada H,
Jing N and Kondoh H: Interplay of SOX and POU factors in regulation
of the Nestin gene in neural primordial cells. Mol Cell Biol.
24:8834–8846. 2004. View Article : Google Scholar : PubMed/NCBI
|
20
|
Frank NY, Margaryan A, Huang Y, Schatton
T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W and Frank MH:
ABCB5-mediated doxorubicin transport and chemoresistance in human
malignant melanoma. Cancer Res. 65:4320–4333. 2005. View Article : Google Scholar : PubMed/NCBI
|
21
|
Clark WH Jr, From L, Bernardino EA and
Mihm MC: The histogenesis and biologic behavior of primary human
malignant melanomas of the skin. Cancer Res. 29:705–727.
1969.PubMed/NCBI
|
22
|
Bastian BC, Olshen AB, LeBoit PE and
Pinkel D: Classifying melanocytic tumors based on DNA copy number
changes. Am J Pathol. 163:1765–1770. 2003. View Article : Google Scholar : PubMed/NCBI
|
23
|
Curtin JA, Busam K, Pinkel D and Bastian
BC: Somatic activation of KIT in distinct subtypes of melanoma. J
Clin Oncol. 24:4340–4346. 2006. View Article : Google Scholar : PubMed/NCBI
|
24
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
25
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
26
|
Santi R, Simi L, Fucci R, Paglierani M,
Pepi M, Pinzani P, Merelli B, Santucci M, Botti G, Urso C and Massi
D: KIT genetic alterations in anorectal melanomas. J Clin Pathol.
68:130–134. 2015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Yang HM, Hsiao SJ, Schaeffer DF, Lai C,
Remotti HE, Horst D, Mansukhani MM and Horst BA: Identification of
recurrent mutational events in anorectal melanoma. Mod Pathol.
30:286–296. 2017. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al: Improved survival with vemurafenib in melanoma with BRAF V600E
mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
|
29
|
Richter A, Grieu F, Carrello A, Amanuel B,
Namdarian K, Rynska A, Lucas A, Michael V, Bell A, Fox SB, et al: A
multisite blinded study for the detection of BRAF mutations in
formalin-fixed, paraffin-embedded malignant melanoma. Sci Rep.
3:16592013. View Article : Google Scholar : PubMed/NCBI
|
30
|
Clark WH Jr, Elder DE, Guerry D IV,
Braitman LE, Trock BJ, Schultz D, Synnestvedt M and Halpern AC:
Model predicting survival in stage I melanoma based on tumor
progression. J Natl Cancer Inst. 81:1893–1904. 1989. View Article : Google Scholar : PubMed/NCBI
|
31
|
Tariq MU, Ud Din N, Ud Din NF, Fatima S
and Ahmad Z: Malignant melanoma of anorectal region: A
clinicopathologic study of 61 cases. Ann Diagn Pathol. 18:275–281.
2014. View Article : Google Scholar : PubMed/NCBI
|
32
|
Chu VH, Tetzlaff MT, Torres-Cabala CA,
Prieto VG, Bassett R Jr, Gershenwald JE, McLemore MS, Ivan D, Wang
WL, Ross MI and Curry JL: Impact of the 2009 (7th edition) AJCC
melanoma staging system in the classification of thin cutaneous
melanomas. Biomed Res Int. 2013:8987192013. View Article : Google Scholar : PubMed/NCBI
|
33
|
Mandalà M, Galli F, Cattaneo L, Merelli B,
Rulli E, Ribero S, Quaglino P, de Giorgi V, Pigozzo J, Sileni VC,
et al: Mitotic rate correlates with sentinel lymph node status and
outcome in cutaneous melanoma greater than 1 millimeter in
thickness: A multi-institutional study of 1524 cases. J Am Acad
Dermatol. 76:264–73.e2. 2017. View Article : Google Scholar : PubMed/NCBI
|
34
|
Girouard SD, Laga AC, Mihm MC, Scolyer RA,
Thompson JF, Zhan Q, Widlund HR, Lee CW and Murphy GF: SOX2
contributes to melanoma cell invasion. Lab Invest. 92:362–370.
2012. View Article : Google Scholar : PubMed/NCBI
|
35
|
Santini R, Pietrobono S, Pandolfi S,
Montagnani V, D'Amico M, Penachioni JY, Vinci MC, Borgognoni L and
Stecca B: SOX2 regulates self-renewal and tumorigenicity of human
melanoma-initiating cells. Oncogene. 33:4697–4708. 2014. View Article : Google Scholar : PubMed/NCBI
|
36
|
Setia N, Abbas O, Sousa Y, Garb JL and
Mahalingam M: Profiling of ABC transporters ABCB5, ABCF2 and
nestin-positive stem cells in nevi, in situ and invasive melanoma.
Mod Pathol. 25:1169–1175. 2012. View Article : Google Scholar : PubMed/NCBI
|
37
|
Matsuda Y, Ishiwata T, Yoshimura H,
Yamahatsu K, Minamoto T and Arai T: Nestin phosphorylation at
threonines 315 and 1299 correlates with proliferation and
metastasis of human pancreatic cancer. Cancer Sci. 108:354–361.
2017. View Article : Google Scholar : PubMed/NCBI
|
38
|
Akiyama M, Matsuda Y, Ishiwata T, Naito Z
and Kawana S: Nestin is highly expressed in advanced-stage
melanomas and neurotized nevi. Oncol Rep. 29:1595–1599. 2013.
View Article : Google Scholar : PubMed/NCBI
|
39
|
Ladstein RG, Bachmann IM, Straume O and
Akslen LA: Nestin expression is associated with aggressive
cutaneous melanoma of the nodular type. Mod Pathol. 27:396–401.
2014. View Article : Google Scholar : PubMed/NCBI
|
40
|
Akiyama M, Matsuda Y, Ishiwata T, Naito Z
and Kawana S: Inhibition of the stem cell marker nestin reduces
tumor growth and invasion of malignant melanoma. J Invest Dermatol.
133:1384–1387. 2013. View Article : Google Scholar : PubMed/NCBI
|
41
|
Anwar MA, Murad F, Dawson E, Abd Elmageed
ZY, Tsumagari K and Kandil E: Immunohistochemistry as a reliable
method for detection of BRAF-V600E mutation in melanoma: A
systematic review and meta-analysis of current published
literature. J Surg Res. 203:407–415. 2016. View Article : Google Scholar : PubMed/NCBI
|